BioCardia, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BioCardia, Inc. (BCDA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-24
- BioCardia, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.40M, a 33.33% increase from fiscal 2024.
- BioCardia, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.80M, a 33.33% decline from fiscal 2023.
- BioCardia, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.70M, a 6.90% decline from fiscal 2022.
- BioCardia, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.90M, a 7.41% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.40M 10-K · filed 2026-03-24 | |
| 2024-12-31 | $1.80M 10-K · filed 2026-03-24 | |
| 2023-12-31 | $2.70M 10-K · filed 2025-03-26 | |
| 2022-12-31 | $2.90M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $2.70M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $3.30M 10-K · filed 2022-03-29 | |
| 2019-12-31 | $3.20M 10-K · filed 2021-03-30 | |
| 2018-12-31 | $3.20M 10-K · filed 2020-04-09 | |
| 2017-12-31 | $3.00M 10-K · filed 2019-04-02 | -$3.00M 10-K · filed 2018-03-16 |
| 2016-12-31 | $2.80M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $2.70M 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |